Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 8/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098540 | 0.86 | BRD4 (0.40) | BRD4ADRA2AHPGDHSD17B10BRD9 | |
| SCHEMBL7098664 | 0.71 | BRD4 (0.43) | BRD4HPGDHSD17B10BRDT | |
| SCHEMBL28735295 | 0.70 | PTGES2 (0.43) | PTGES2ADRA2ALMNAHPGD | |
| SCHEMBL31104321 | 0.67 | BRD4 (0.40) | BRD4LMNABRD9BRDTBRD7 | |
| SCHEMBL7103532 | 0.67 | BRD4 (0.43) | BRD4LMNABRD9BRDTBRD7 | |
| SCHEMBL2370165 | 0.67 | KDM4E (0.45) | BRD4LMNAHSD17B10BRD9BRDT | |
| SCHEMBL6686475 | 0.67 | BRD4 (0.42) | BRD4LMNAHPGDHSD17B10BRD9 | |
| SCHEMBL7104848 | 0.67 | ADRA2A (0.33) | BRD4ADRA2A | |
| SCHEMBL7410003 | 0.67 | ALDH1A1 (0.59) | BRD4LMNAHPGD | |
| SCHEMBL7149178 | 0.67 | BRD4 (0.34) | BRD4LMNAHPGDHSD17B10BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1102754-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | PTGES2 2445/4885BRD4 26/4885ADRA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.